Interventional × Myeloproliferative Disorders × Classical hematology × Clear all
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts
NCT05972577 2026-04-06

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Ohio State University Comprehensive Cancer Center

Phase NA Completed
30 enrolled
NCT01758042 2026-03-06

BMT

Massachusetts General Hospital

Phase NA Completed
10 enrolled
NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Dartmouth-Hitchcock Medical Center

Phase 3 Active not recruiting
21 enrolled 19 charts
NCT03622788 2025-12-17

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
16 enrolled
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
300 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
35 enrolled 14 charts
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00816413 2023-08-14

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

University of Nebraska

Phase 1/2 Withdrawn
NCT00045305 2023-06-28

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Eastern Cooperative Oncology Group

Phase 2 Completed
17 enrolled 10 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT00003816 2021-08-13

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Roswell Park Cancer Institute

Phase 2/3 Completed
361 enrolled 16 charts
NCT00005797 2020-12-10

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
125 enrolled
NCT00054236 2020-07-27

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Case Comprehensive Cancer Center

Phase 1 Completed
55 enrolled
NCT00068523 2020-07-27

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase NA Completed
10 enrolled
NCT01866839 2020-07-21

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
41 enrolled 21 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00053989 2020-02-10

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Roswell Park Cancer Institute

Phase 2 Completed
41 enrolled 13 charts
NCT00397813 2020-01-31

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Fred Hutchinson Cancer Center

Phase 2 Completed
77 enrolled 16 charts
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT00856388 2019-11-13

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Roswell Park Cancer Institute

Phase NA Completed
62 enrolled 14 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01499147 2018-11-08

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

University of Illinois at Chicago

Phase NA Completed
100 enrolled 10 charts
NCT00425477 2018-10-05

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
26 enrolled 7 charts
NCT01273766 2018-09-07

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Wake Forest University Health Sciences

Phase 2 Completed
16 enrolled 10 charts
NCT00134017 2018-08-31

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
142 enrolled 11 charts